Home › Kanser sa Tiyan › New York › New York City
Pag-aaral pangklinika para sa Kanser sa Tiyan sa New York City, NY
Isang pag-aaral para sa Kanser sa Tiyan ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa New York City. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
- Memorial Sloan Kettering Hospital, New York
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Nagre-recruitPhase 2/3
- Memorial Sloan Kettering Cancer Center, New York
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Nagre-recruitPhase 3
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Nagre-recruitPhase 2/3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Rockefeller Outpatient Pavilion (53rd Street), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Nagre-recruitPhase 2
- Research Site, New York
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Nagre-recruitPhase 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nagre-recruitPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Nagre-recruitPhase 3
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Nagre-recruitPhase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Nagre-recruitPhase 1
- Icahn School of Medicine at Mount Sinai, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Hospital, New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Nagre-recruitPhase 1
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Nagre-recruitPhase 3
- Memorial Sloan Kettering Cancer Center - MAIN, New York
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Nagre-recruitPhase 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Nagre-recruitPhase 2
- Research Site, New York
Brodalumab in the Treatment of Immune-Related Adverse Events
Nagre-recruitPhase 1
- Columbia University Irving Medical Center, New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Nagre-recruitPhase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study Collecting Health Information to Understand and Prevent Gastric Cancer
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
Avutometinib and Defactinib in Diffuse Gastric Cancer
Nagre-recruitPhase 2
- Columbia University Irving Medical Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, New York
Comprehensive Outcomes for After Cancer Health
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Memorial Sloan Kettering Cancer Center, New York
Pag-aaral para sa Kanser sa Tiyan sa ibang lungsod
- Houston, TX42 pag-aaral
- Boston, MA32 pag-aaral
- Nashville, TN28 pag-aaral
- Baldwin Park, CA22 pag-aaral
- Los Angeles, CA22 pag-aaral
- Arlington, VA20 pag-aaral
- Dallas, TX19 pag-aaral
- San Antonio, TX19 pag-aaral
- St. Louis, MO18 pag-aaral
- Grand Rapids, MI18 pag-aaral
- Washington, DC16 pag-aaral
- Chicago, IL16 pag-aaral
Iba pang pag-aaral sa New York City
- Kanser sa Suso136 pag-aaral
- Non-Small Cell Lung Cancer121 pag-aaral
- Kanser (lahat ng uri)109 pag-aaral
- Kanser sa Prostate103 pag-aaral
- Metastatic Cancer93 pag-aaral
- Colorectal Cancer78 pag-aaral
- Kanser sa Ovary69 pag-aaral
- Kanser sa Baga60 pag-aaral
- Multiple Myeloma60 pag-aaral
- Kanser sa Pancreas60 pag-aaral
- Kanser ng Endometrium52 pag-aaral
- Acute Myeloid Leukemia51 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.